Unbiased Analysis of Today's Healthcare Issues
Today I attended the very interesting ISPOR Health Policy Leadership Exchange (HPLE) in Washington DC on the topic of Most Favored Nation (MFN). There were a number of important points made and I’ll summarize a few of them. First, US drug prices are much higher than in other OECD countries. An ASPE report from 2024…
That is the title of my new Health Affairs Forefront piece out today with Lou Garrison and Richard Xie. An excerpt from the article is below: United States policy makers increasingly argue that Americans pay too much for prescription drugs. In a recent report, the Senate Health, Education, Labor, and Pensions (HELP) Committee minority staff contended…
It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the previous 10 months…Delaying launches at lower EU prices could help secure higher U.S. prices for longer. You can read the full…
That is the question asked by a 2022 NBER working paper by Pierre Dubois, Ashvin Gandhi and Shoshana Vasserman. Methodology: Demand Side Model The authors used IQVIA data on revenues and quantities of drugs sold to hospitals from 2002 to 2013 across US, Canada, France, Germany, Italy, Spain and UK markets. The authors define a…
How will HEOR leaders respond to recent policy changes? A survey from Tufts and the Center for the Evaluation of Value and Risk in Health (CEVR) provides the answer. About 2/3 of the n=57 respondents were Head of their HEOR department and the remaining 1/3 had some other senior level HEOR role. Whereas 29.8% of…
The Trump administration has introduced three most-favored-nation (MFN) drug pricing initiatives designed to link U.S. pharmaceutical costs to prices paid in economically comparable countries. Most-favored-nation pricing requires manufacturers to provide rebates when U.S. prices exceed those in reference nations—a direct response to the persistent gap between U.S. drug prices and those in other developed economies.…